Christopher H Gibbons, Todd Levine, Charles Adler, Bailey Bellaire, Ningshan Wang, Jade Stohl, Pinky Agarwal, Georgina M Aldridge, Alexandru Barboi, Virgilio G H Evidente, Douglas Galasko, Michael D Geschwind, Alejandra Gonzalez-Duarte, Ramon Gil, Mark Gudesblatt, Stuart H Isaacson, Horacio Kaufmann, Pravin Khemani, Rajeev Kumar, Guillaume Lamotte, Andy J Liu, Nikolaus R McFarland, Mitchell Miglis, Adam Reynolds, Gregory A Sahagian, Marie-Helene Saint-Hillaire, Julie B Schwartzbard, Wolfgang Singer, Michael J Soileau, Steven Vernino, Oleg Yerstein, Roy Freeman
IMPORTANCE: Finding a reliable diagnostic biomarker for the disorders collectively known as synucleinopathies (Parkinson disease [PD], dementia with Lewy bodies [DLB], multiple system atrophy [MSA], and pure autonomic failure [PAF]) is an urgent unmet need. Immunohistochemical detection of cutaneous phosphorylated α-synuclein may be a sensitive and specific clinical test for the diagnosis of synucleinopathies. OBJECTIVE: To evaluate the positivity rate of cutaneous α-synuclein deposition in patients with PD, DLB, MSA, and PAF...
March 20, 2024: JAMA